首页> 外文期刊>Essays in Biochemistry >Therapeutic approaches to the modulation of apoptosis
【24h】

Therapeutic approaches to the modulation of apoptosis

机译:调节细胞凋亡的治疗方法

获取原文
获取原文并翻译 | 示例
       

摘要

The appreciation of the role of apoptosis in the vast majority of diseases affecting humans has revolutionized the discovery and development of drugs targeting inflammation and oncology.Novel therapeutic approaches to modulate disease by regulating apoptosis are currently being tested in pre-clinical and clinical settings.Enthusiasm for some of these therapies is reflected in the fact that they have received U.S.Food and Drug Administration approval in record time.Approaches include the traditional use of small molecules to target specific players in the apoptosis cascade.They also include radical new approaches such as using antisense molecules to inhibit production of the Bcl-2 protein or antibodies that ligate either death receptors,such as TRAIL (tumour necrosis factor-related apoptosis-inducing ligand),or the MHC (HLA-DR),resulting in the initiation of apoptosis of target cells.Antibodies targeting cell-specific antigens are being used in conjunction with radioactive isotopes to deliver a more specific chemotherapy,particularly in the case of B-cell lymphomas.Other therapies target mitochondria,a key organelle in the apoptosis cascade.This diverse range of therapies includes photodynamic therapy,retinoic acid and arsenic trioxide,all of which induce apoptosis by generating reactive oxygen species.As our understanding of apoptosis incrases,further opportunities will arise for tailor-made thereapies that will result in improved clinical outcome without hte devastating side effects of current interventions.
机译:对细胞凋亡在影响人类的绝大多数疾病中的作用的认识已经彻底改变了针对炎症和肿瘤学的药物的发现和开发。目前正在临床前和临床环境中测试通过调节细胞凋亡来调节疾病的新型治疗方法。这些疗法中的一些体现在他们在创纪录的时间内获得了美国食品药品监督管理局(USFood and Drug Administration)批准的事实,包括传统上使用小分子靶向凋亡级联反应中的特定参与者的方法,还包括一些激进的新方法,例如使用抑制Bcl-2蛋白或连接死亡受体的抗体(例如TRAIL(肿瘤坏死因子相关的凋亡诱导配体)或MHC(HLA-DR))产生反义分子,从而导致Bcl-2蛋白或MHC(HLA-DR)的凋亡靶向细胞特异性抗原的抗体正与放射性同位素一起用于d尤其是在B细胞淋巴瘤的情况下,可以提供更特异性的化学疗法。其他疗法针对线粒体,它是细胞凋亡级联反应中的关键细胞器。随着我们对细胞凋亡增加的了解,定制疗法的进一步机会将出现,这将导致临床结果得到改善,而不会造成当前干预措施的破坏性副作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号